Carriage of multidrug-resistant Streptococcus pneumoniae and impact of chemoprophylaxis during an outbreak of meningitis at a day care center

Clinical Infectious Diseases

Volumn 29, Issue 5, 1999, Pages 1257-1264

  Craig, Allen S ^a,c,d   Erwin, Paul C ^c   Schaffner, William ^d   Elliott, John A ^b   Moore, William L ^c   Ussery, Xilla T ^f   Patterson, Lori ^f   Dake, Anthony D ^d,g   Hannah, Stuart G ^e   Butler, Jay C ^b  

^a Epidemiology and Analysis Program Office   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c TENNESSEE DEPARTMENT OF HEALTH   (United States)

^d Department of Preventive Medicine ^*  (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f East Tennessee Children's Hospital   (United States)

^g Good Samaritan Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; RIFAMPICIN;

ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; CHEMOPROPHYLAXIS; DRUG EFFICACY; EPIDEMIC; FEMALE; HUMAN; INFANT; INFECTION RISK; MALE; MENINGITIS; MULTIDRUG RESISTANCE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0033496296     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313451     Document Type: Article

References (51)

1. 1. Alsonso deVelasco E, Verheul AFM, Verhoef J, Snippe H. Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev 1995;59:591-603.
2. 2. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997;337:970-6.
3. 3. Finland M. Pneumococcal infections, In; Evans AS, Feldman HA, eds. Bacterial infections of humans. New York: Plenum Press, 1982;417-33.
4. 4. Naraqi S, Kirkpatrick GP, Kabins S. Relapsing pneumococcal meningitis: isolation of an organism with decreased susceptibility to penicillin G. J Pediatr 1974;85:671-3.
5. 5. Radetsky MS, Johansen TL, Lauer BA, et al. Multiply resistant pneumococcus causing meningitis: its epidemiology within a day-care centre. Lancet 1981;1:771-3.
6. 6. Butler JC, Hofmann J, Cetron MS, et al. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers tor Disease Control and Prevention's Pneumococcal Sentinel Surveillance System, J Infect Dis 1996;174:986-93.
7. 7. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271:1831-5.
8. 8. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995;333:481-6.
9. 9. Kaplan SL, Mason EO Jr, Barson WJ, et al. Three-year multicenter surveillance of systemic pneumococcal infections in children. Pediatrics 1998;102:538-45.
10. 10. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program, Clin Infect Dis 1998;27:764-70.
11. 11. Mufson MA. Penicillin-resistant Streptococcus pneumoniae increasingly threatens the patient and challenges the physician [editorial]. Clin Infect Dis 1998;27:771-3.
12. 12. Gessner BD, Ussery XT, Parkinson AJ, Breiman RF. Risk factors for invasive disease caused by Streptococcus pneumoniae among Alaskan native children younger than two years of age. Pediatr Infect Dis J 1995;14:123-8.
13. 13. Takala AK, Jero J, Kela E, Ronnberg P, Koskenniemi E, Eskola J. Risk factors for primary invasive pneumococcal disease among children in Finland, JAMA 1995;273:859-64.
14. 14. Cherian T, Steinhoff MC, Harrison LH, Rohn D, McDougal LK, Dick J, A cluster of invasive pneumococcal disease in young children in child care. JAMA 1994;271:695-7.
15. 15. Rauch AM, O'Ryan M, Van R, Pickering LK. Invasive disease due to multiply resistant Streptococcus pneumoniae in a Houston, Tex, day-care center. Am J Dis Child 1990;144:923-7.
16. 16. Centers for Disease Control and Prevention. Hemorrhage and shock associated with invasive pneumococcal infection in healthy infants and children New Mexico, 1993 1994. MMWR Morb Mortal Wkly Rep 1995;43:949-52.
17. 17. Boken DJ, Chartrand SA, Goering RV, Kruger R, Harrison CJ, Colonization with penicillin-resistant Streptococcus pneumoniae in a child-care center. Pediatr Infect Dis J 1995;14:879-84.
18. 18. Arnold KE, Leggiadro RJ, Breiman RF, et al. Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee. J Pediatr 1996;128:757-64.
19. 19. Hoge C.W, Reichler MR, Dominguez F.A, et al. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. N Engl J Med 1994;331:643-8.
20. 20. DeMaria A Jr, Browne K, Bert SL, Sherwood EJ, McCabe WR. An outbreak of type 1 pneumococcal pneumonia in a men's shelter. JAMA 1980;244: 1446-9.
21. 21. Mercat A, Nguyen J, Dautzenberg B. An outbreak of pneumococcal pneumonia in two men's shelters. Chest 1991;99:147-51.
22. 22. Facklam RR, Washington JA II, Streptococcus and related catalase-negative gram positive cocci. In: Balows A, Hausler WJ, Hermann RL, Isenberg HD, Shadomy HJ, eds. Manual of clinical microbiology, 5th ed. Washington, DC: American Society tor Microbiology, 1991:238-57.
23. 23. Hermans PWM, Sluijter M, Hoogenboezem T, Heersma H, van Belkum A, de Groot R. Comparative study of live different DNA lingerprint techniques for molecular typing of Streptococcus pneumoniae. J Clin Microbiol 1995;33:1606-12.
24. 24. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow acrobically: approved standard. NCCLS documents M100-S5, M7-A3. 3rd ed. Villanova, PA: National Committee for Clinical Laboratory Standards, 1994.
25. 25. Centers for Disease Control and Prevention, Defining the public health impact of drug-resistant Streptococcus pneumoniae report of a working group. MMWR Morb Mortal Wkly Rep 1996;45(RR-1):1-20.
26. 26. Levine OS, Farley M, Harrison LH, et al. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics 1999;103:e28-38.
27. 27. Reichler MR, Allphin AA, Breiman RF, et al. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio. J Infect Dis 1992;166:1346-53.
28. 28. Tenover FC, Arbeit RD, Gocring RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233-9.
29. 29. Gray BM, Converse GM III, Dillon HC Jr. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 1980;142:923-33.
30. 30. Krasinski K, Nelson JD, Butler S, Luby JP, Kusmiesz H. Possible association of mycoplasma and viral respiratory infections with bacterial meningitis. Am J Epidemiol 1987;125:499-508.
31. 31. Fiore A, Inverson C. Anderson B, et al. Outbreak of pneumonia in a nursing home: antecedent human parainfluenza virus 1 (HPLV1) infection may predispose to pneumonia [abstract no. K-3]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996.
32. 32. American Academy of Pediatrics. Pneumococcal infections. In: Peter G, ed. 1997 red book: report of the committee on infectious diseases. 24th ed. Elk Grove, II.: American Academy of Pediatrics, 1997:410-9.
33. 33. Nuorti P, Butler JC, Crutcher M. et al. An outbreak of pneumonia and bacteremia due to multi-drug resistant Streptococcus pneumoniae among unvaccinated nursing home residents. N Engl J Med 1998;338:1861-8.
34. 34. Citron KM, May JR. Rifamycin antibiotics in chronic purulent bronchitis. Lancet 1969;2:982-3.
35. 35. Jacobs MR, Koornhof HJ, Robins-Browne RM, Stevenson CM, Vermaak ZA, Freirnan I. Emergence of multiply resistant pneumococci. N Engl J Med 1978;299:735-40.
36. 36. Ekdahl K, Ahlinder I, Hansson HB, Melander E, Mölstad S, Söderström M, et al. Duration of nasopharyngeal carriage of penicillin-resistan Streptococcus pneumoniae: experiences from the south Swedish pneumococcal intervention project. Clin Infect Dis 1997;25:1113-7.
37. 37. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992;165(suppl 1):S49-52.
38. 38. Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. Science 1994;265:1385-7.
39. 39. Douglas RM. Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983;148:131-7.
40. 40. Children's Vaccine Initiative. A pneumococcal vaccine to save children of all ages nears final testing. CVI Forum 1996;13:3-11.
41. 41. Butler JC, Breiman RF, Lipman HB, Hofmann J, Facklam RR. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978 1994: implications for development of a conjugate vaccine. J Infect Dis 1995;171:885-9.
42. 42. Zangwill KM, Vadheim CM. Vannier AM, Hemenway LS, Greenberg DP, Ward JI. Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J Infect Dis 1996;174:752-9.
43. 43. Käyhty H, Eskola J. New vaccines for the prevention of pneumococcal infections. Emerg Infect Dis 1996;2:289-98.
44. 44. Baltimore RS. New challenges in the development of conjugate pneumococcal vaccine. JAMA 1992;268:3366-7.
45. 45. Anderson EL, Kennedy DJ, Geldmacher KM, Donnelly J, Mendelman PM. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996;128:649-53.
46. 46. Steinhoff MC, Edwards K, Keyserling H, et al. A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics, Pediatr Infect Dis J 1994;13:368-72.
47. 47. Käyhty H, Åhman H, Rönnberg P, Tillikainen R, Eskola J. Pneumococcal polysaccharide meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis 1995; 172:1273-8.
48. 48. Leach A, Ceesay SJ, Banya WA, Greenwood BM. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gamhian infants. Pediatr Infect Dis J 1996;15:333-9.
49. 49. Black SB, Shinefield H, Ray P, Lewis E, Fireman B. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: results of the Northern California Kaiser Permanente Efficacy Trial [abstract no. LB-9]. In: Program and abstracts of the 38th Enterscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998.
50. 50. Dagan R, Mclamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococeal vaccine. J Infect Dis 1996;174:1271-8.
51. 51. Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P. Reduction of pneumococcal nasopharyngcal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 1997;16:1060-4.